AXIM (AXIM Biotechnologies) Margin of Safety % (DCF FCF Based): N/A (As of Jun. 25, 2026)


What is AXIM Biotechnologies Margin of Safety % (DCF FCF Based)?

Margin of Safety % (DCF FCF Based) = (Intrinsic Value: DCF (FCF Based) - Current Price) / Intrinsic Value: DCF (FCF Based).

Note: Discounted FCF model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

AXIM Biotechnologies's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF FCF Based) is not calculated.

AXIM vs HEPA, SCNI, BZYR: Margin of Safety % (DCF FCF Based) Comparison

For the Biotechnology subindustry, AXIM Biotechnologies's Margin of Safety % (DCF FCF Based), along with its competitors' market caps and Margin of Safety % (DCF FCF Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AXIM Biotechnologies Margin of Safety % (DCF FCF Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AXIM Biotechnologies's Margin of Safety % (DCF FCF Based) distribution charts can be found below:

* The bar in red indicates where AXIM Biotechnologies's Margin of Safety % (DCF FCF Based) falls into.


AXIM Biotechnologies Business Description

Address 6048 Cornerstone Court West, Suite E1, San Diego, CA, USA, 92121
AXIM Biotechnologies Inc is a integrated research and development company and developer of diagnostic healthcare solutions serving to enhance the health of people. The company focuses on improving the landscape for the diagnosis of ophthalmological conditions such as Dry Eye Disease through rapid diagnostic tests. Additionally, The company owns IP and has conducted research on SARS-CoV-2 (COVID-19) rapid neutralizing antibody tests to detect levels of functional neutralizing antibodies that are believed to prevent SARS-CoV-2 from entering the host cells.